Core Viewpoint - Cinda Biologics has entered into a strategic partnership with Eli Lilly to advance global research and development of innovative drugs in oncology and immunology, which is expected to enhance their long-term collaboration and drive growth in the biopharmaceutical sector [1] Group 1: Financial Terms of the Agreement - Cinda Biologics will receive an upfront payment of $350 million from Eli Lilly [1] - The agreement includes potential milestone payments totaling up to approximately $8.5 billion, contingent upon achieving specific development, regulatory, and commercialization milestones [1] - Cinda Biologics is entitled to a tiered sales share from net sales outside Greater China for each product [1] Group 2: Collaborative Efforts and Responsibilities - This partnership marks the seventh collaboration between Cinda Biologics and Eli Lilly, further deepening their productive relationship [1] - Cinda Biologics will leverage its established antibody technology platform and efficient clinical capabilities to lead the projects from drug discovery to clinical concept verification (completion of Phase II trials) [1] - Eli Lilly will obtain exclusive global development and commercialization rights for the relevant projects outside Greater China, while Cinda Biologics retains all rights within Greater China [1]
港股异动 | 信达生物(01801)高开逾4% 与礼来制药达成战略合作 潜在交易额高达88.5亿美元